Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 23 |
| Active Pipeline (Recruiting Now) | 15 (11) |
| Completed vs Stopped Early | 7 / 1 (4.3%) |
| Median Closed Actual Enrollment | 58 participants |
| Physical Hospital Site Disclosure | 93.8% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hunan Cancer Hospital | Changsha, Hunan | 10 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei | 9 |
| Henan Cancer Hospital | Zhengzhou, Henan | 9 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07154264 | A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) | Phase II | RECRUITING |
| NCT07234162 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | Phase III | RECRUITING |
| NCT05712902 | Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) | Phase II | ACTIVE NOT RECRUITING |
| NCT06511869 | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Dizal Pharmaceuticals Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.